Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
×
254 Results
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.
The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.
Analysis showed that the VeriStrat test was able to identify patients more likely to have a slower progression of disease with select treatments.
The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.
Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.
Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.
VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).